Q4 2019 NeuroMetrix Inc Earnings Call
NeuroMetrix, Inc. (NURO) today announced the effectiveness of a one-for-ten reverse split of its common stock. The shares underlying the Company's outstanding options and warrants will also be adjusted accordingly. The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2020 first quarter financial results before the opening of the market on Thursday, April 23, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on April 23, 2020 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 6528139.
Shai Gozani has been the CEO of NeuroMetrix, Inc. (NASDAQ:NURO) since 1997. This report will, first, examine the CEO...
NeuroMetrix, Inc. (NURO) today announced that, due to the public health impact of the COVID-19 pandemic and in accordance with orders issued by the Governor of the Commonwealth of Massachusetts, the Company’s 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held in a virtual meeting format only. The link to the virtual meeting is http://viewproxy.com/neurometrix/2020/vm. As described in the proxy materials for the Annual Meeting previously distributed, you are entitled to participate in the Annual Meeting if you were a shareholder as of the close of business on March 2, 2020, the record date, or hold a legal proxy for the meeting provided by your bank, broker, or nominee.
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
WOBURN, Mass., March 05, 2020 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the recent publication of three additional DPNCheck clinical studies. DPNCheck is a.
NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2019 fourth quarter and full year financial results before the opening of the market on Thursday, January 23, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on January 23, 2020 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 6728609.
NEW YORK, NY / ACCESSWIRE / April 23, 2020 / NeuroMetrix, Inc. (NASDAQ:NURO) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on April 23, 2020 at 8:00 AM ...
Once considered one of the state’s fastest-growing public companies, a Woburn medical device company has made a series of substantial cuts over the last year in the hopes of bringing the company out of the red.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...
If you're interested in NeuroMetrix, Inc. (NASDAQ:NURO), then you might want to consider its beta (a measure of share...
WOBURN, Mass., Feb. 25, 2020 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the American Academy of Pain Medicine (AAPM) 36th.
WOBURN, Mass., April 23, 2020 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2020. The Company is a.
NeuroMetrix, Inc. (NURO) today announced that Quell technology has been selected for use in a large, NIH-funded, randomized, pragmatic clinical trial of TENS for fibromyalgia. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep and mood disturbances. Although several drugs are approved for treating fibromyalgia pain, there is an unmet need for safe, non-pharmacological options.
NeuroMetrix, Inc. (NURO) today provided an update on its Quell technology commercial strategy and pipeline. An estimated 100 million US adults have chronic pain. People with chronic pain may also have low quality sleep, anxiety, depression, and poor overall health.
Q1 2020 NeuroMetrix Inc Earnings Call
WOBURN, Mass., Jan. 27, 2020 -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2019. The Company.
NeuroMetrix, Inc. (NURO) today announced the shift of its 2019 financial conference call to Monday, January 27, 2020 at 8:00am Eastern Time. The Company apologized for any inconvenience this may have caused. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 6728609.